| Filed On | Filing |
|---|---|
| 06 Oct 2026 |
8-K: Regulation FD Disclosure
1. MAIA Biotechnology, Inc. (the “Company”) has prepared a presentation (the “Presentation”) that management intends to use from time to time in presentations about the Company’s operations and performance on or after October 6, 2026, wh... |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, MAIA Biotechnology, Inc. (the “Company”) (NYSE American: MAIA) held its 2026 Annual Meeting of stockholders (the “Annual Meeting”). For more information on the proposals, which are described below, please refer to the Co... |
| 14 May 2026 |
8-K: Termination of a Material Definitive Agreement
On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales ... |
| 16 Apr 2026 |
8-K: Other Events
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer |
| 08 Apr 2026 |
8-K: Other Events
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 27, 2026, the Board of Directors of MAIA Biotechnology, Inc. (the “Company”) approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Hea... |
| 31 Mar 2026 |
8-K: Other Events
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer |
| 27 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
MAIA Biotechnology, Inc., (the “Company”) has prepared a poster (the “Poster”) entitled “Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and IC... |
| 04 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement with Konik Capital Partners LLC, a division of T.R. Winston & Company (the “Underwriter,” which term shall also include any underwriter substituted ... |
| 24 Feb 2026 |
8-K: Other Events
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market |
| 20 Jan 2026 |
8-K: Other Events
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum |
| 13 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
MAIA Biotechnology, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that its management intends to use from time to time, including at the Biotech Showcase in San Francisco, California on January 1... |
| 17 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of December 16, 2025, between MAIA Biotechnology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includin... |
| 11 Dec 2025 |
8-K: Other Events
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer |
| 10 Dec 2025 |
8-K: Other Events
CHICAGO – December 10, 2025 - MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (... |
| 21 Nov 2025 |
8-K: Other Events
CHICAGO – November 21, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from t... |
| 20 Nov 2025 |
8-K: Other Events
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation |
| 07 Nov 2025 |
8-K: Other Events
1. MAIA Biotechnology, Inc. (the “Company”) has prepared a poster (the “THIO-104 Poster”) entitled “A Phase 3 Study of Ateganosine (THIO) Sequenced with Immune Checkpoint Inhibitor (ICI) versus Standard of Care Chemotherapy in ICI-Resist... |
| 27 Oct 2025 |
8-K: Other Events
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| 24 Oct 2025 |
8-K: Other Events
MAIA Biotechnology, Inc. (the “Company”) has prepared a poster (the “Poster”) entitled “Presentation 1: A Phase 2 Study of Ateganosine (THIO; 6-thio-2’-deoxyguanosine) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients wit... |
Loading...